Related Experiment Video
Updated: Dec 17, 2025

Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research
Published on: November 3, 2023
The relationship between hyperuricemia and contrast-induced acute kidney injury undergoing primary percutaneous
Wei Guo1,2, Feier Song1, Shiqun Chen1
1Department of Cardiology, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.
Insights
Hyperuricemia may predict contrast-induced acute kidney injury (CI-AKI) and worse outcomes in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (pPCI). This finding suggests potential benefits from lowering serum uric acid levels.
Area of Science:
- Cardiology
- Nephrology
- Biochemistry
Background:
- Contrast-induced acute kidney injury (CI-AKI) is a complication of primary percutaneous coronary intervention (pPCI).
- Hyperuricemia, a condition of elevated serum uric acid (SUA) levels, is common and may impact cardiovascular outcomes.
- The predictive role of hyperuricemia for CI-AKI and subsequent outcomes in pPCI patients requires further investigation.
Purpose of the Study:
- To assess whether hyperuricemia independently predicts CI-AKI in patients with ST-segment elevation myocardial infarction (STEMI) undergoing pPCI.
- To evaluate the association between hyperuricemia and long-term mortality in this patient cohort.
- To explore the potential clinical implications of managing SUA levels in patients undergoing pPCI.
Main Methods:
- Secondary analysis of the ATTEMPT study database, including 560 STEMI patients undergoing pPCI.
- Patients categorized into hyperuricemia (SUA >7 mg/dL in males, >6 mg/dL in females) and normouricemia groups.
- Multivariate logistic and Cox regression analyses used to determine CI-AKI and long-term mortality predictors.
Main Results:
- The study aims to determine the predictive value of hyperuricemia for CI-AKI development.
- It is hypothesized that hyperuricemia will be associated with an increased risk of CI-AKI.
- Long-term mortality is predicted to be higher in hyperuricemic patients post-pPCI, even after adjusting for confounders.
Conclusions:
- This study will elucidate the predictive significance of hyperuricemia for CI-AKI and patient outcomes following pPCI.
- Findings may support the hypothesis that hyperuricemia is an independent risk factor for CI-AKI and adverse long-term outcomes.
- Results could provide evidence for interventions targeting SUA levels to improve CI-AKI and mortality rates in STEMI patients undergoing pPCI.
Background:
Contrast-induced acute kidney injury (CI-AKI) contributes toward unfavorable clinical outcomes after primary percutaneous coronary intervention (pPCI). We will assess whether hyperuricemia is an independent predictor of CI-AKI and outcomes in patients undergoing pPCI.
Methods/Design:
Our study is a secondary analysis for the database from ATTEMPT study, enrolling 560 ST-segment elevation myocardial infarction (STEMI) patients undergoing pPCI. Patients will be divided into 2 groups according to the admission serum uric acid (SUA) level. Hyperuricemia will be defined as a SUA level > 7 mg/dL (417 mmol/L) in males and > 6 mg/dL (357 mmol/L) in females. The primary endpoint was CI-AKI, defined as > 25% or 0.5 mg/dL increase in serum creatinine from baseline during the first 48-72 h post-procedurally. Multivariate analyses for CI-AKI and long-term mortality will be performed using the logistic regression and Cox regression analyses, respectively.
Discussion:
This study will determine the predictive value of hyperuricemia for the development of CI-AKI and outcomes in patients with STEMI undergoing pPCI. We predict that hyperuricemia will be associated with a risk of CI-AKI in patients with pPCI. Furthermore, after adjusting for other variables, long-term mortality after pPCI may be higher in those with hyperuricemia than in those with normouricemia. Results of this study may provide scientific evidence for the effect of hyperuricemia on CI-AKI and long-term outcomes, thereby offering the potential possibility of lowering SUA on the development of CI-AKI and outcomes.
Trial Registration:
ClinicalTrials.gov NCT02067195, Registered on 20 February 2014.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Cardiac Catheterization I: Pre-Procedure Overview
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction
Imaging Studies VII: Vascular Imaging
Acute Kidney Injury V: Interprofessional Care

